Free Trial

Iovance Biotherapeutics (IOVA) Competitors

Iovance Biotherapeutics logo
$1.70 -0.05 (-2.86%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$1.70 +0.00 (+0.06%)
As of 07/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IOVA vs. ARWR, TWST, APLS, VCEL, RXRX, NAMS, APGE, DNLI, KNSA, and CGON

Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

Iovance Biotherapeutics vs. Its Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

In the previous week, Iovance Biotherapeutics had 29 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 31 mentions for Iovance Biotherapeutics and 2 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.59 beat Iovance Biotherapeutics' score of 0.04 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Iovance Biotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
27 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arrowhead Pharmaceuticals currently has a consensus target price of $43.71, suggesting a potential upside of 159.59%. Iovance Biotherapeutics has a consensus target price of $12.22, suggesting a potential upside of 618.95%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Iovance Biotherapeutics
0 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

Iovance Biotherapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$545.21M4.27-$599.49M-$1.40-12.03
Iovance Biotherapeutics$164.07M3.46-$372.18M-$1.24-1.37

Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -176.49%. Arrowhead Pharmaceuticals' return on equity of -45.33% beat Iovance Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead PharmaceuticalsN/A -45.33% -12.49%
Iovance Biotherapeutics -176.49%-49.71%-39.18%

Summary

Arrowhead Pharmaceuticals beats Iovance Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IOVA vs. The Competition

MetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$584.39M$2.91B$5.52B$9.02B
Dividend YieldN/A2.44%5.24%4.07%
P/E Ratio-1.3720.4427.2220.04
Price / Sales3.46181.20380.3292.37
Price / CashN/A41.7026.2128.59
Price / Book0.737.397.945.55
Net Income-$372.18M-$55.04M$3.17B$248.49M
7 Day Performance-2.30%2.51%1.81%4.87%
1 Month Performance-17.07%-0.21%1.28%6.63%
1 Year Performance-76.71%3.41%33.57%20.38%

Iovance Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IOVA
Iovance Biotherapeutics
4.7408 of 5 stars
$1.70
-2.9%
$12.22
+619.0%
-76.6%$584.39M$164.07M-1.37500Trending News
ARWR
Arrowhead Pharmaceuticals
3.749 of 5 stars
$15.99
-0.6%
$43.71
+173.4%
-34.1%$2.21B$3.55M-11.42400
TWST
Twist Bioscience
4.5231 of 5 stars
$36.69
+2.1%
$50.40
+37.4%
-26.6%$2.20B$312.97M-11.29990News Coverage
Positive News
APLS
Apellis Pharmaceuticals
4.4128 of 5 stars
$17.45
+0.1%
$40.05
+129.5%
-51.9%$2.19B$781.37M-9.75770
VCEL
Vericel
2.9457 of 5 stars
$43.37
+3.9%
$61.14
+41.0%
-15.6%$2.18B$237.22M1,446.15300
RXRX
Recursion Pharmaceuticals
1.7426 of 5 stars
$5.07
+0.8%
$7.00
+38.1%
-32.7%$2.06B$58.84M-2.86400
NAMS
NewAmsterdam Pharma
2.2444 of 5 stars
$18.24
-1.8%
$42.89
+135.1%
-2.7%$2.05B$45.56M-9.704Positive News
Analyst Upgrade
APGE
Apogee Therapeutics
2.917 of 5 stars
$44.12
+1.7%
$94.60
+114.4%
+3.2%$2.03BN/A-12.2691Trending News
Analyst Forecast
Options Volume
DNLI
Denali Therapeutics
4.5096 of 5 stars
$13.98
-0.9%
$33.71
+141.2%
-32.6%$2.03BN/A-5.24430News Coverage
KNSA
Kiniksa Pharmaceuticals International
3.3992 of 5 stars
$27.56
-1.7%
$38.80
+40.8%
+44.4%$2.01B$423.24M-110.24220Analyst Upgrade
CGON
CG Oncology
2.3347 of 5 stars
$26.11
+0.6%
$58.67
+124.7%
-17.7%$1.99B$1.14M-17.2961Gap Down

Related Companies and Tools


This page (NASDAQ:IOVA) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners